HK1162522A1 - Oxidant resistant apolipoprotein a-1 and mimetic peptides a-1 - Google Patents

Oxidant resistant apolipoprotein a-1 and mimetic peptides a-1

Info

Publication number
HK1162522A1
HK1162522A1 HK12102352.4A HK12102352A HK1162522A1 HK 1162522 A1 HK1162522 A1 HK 1162522A1 HK 12102352 A HK12102352 A HK 12102352A HK 1162522 A1 HK1162522 A1 HK 1162522A1
Authority
HK
Hong Kong
Prior art keywords
apolipoprotein
mimetic peptides
oxidant resistant
oxidant
resistant
Prior art date
Application number
HK12102352.4A
Other languages
English (en)
Chinese (zh)
Inventor
．史密斯
．哈澤恩
Original Assignee
克里夫蘭臨床基金會
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 克里夫蘭臨床基金會 filed Critical 克里夫蘭臨床基金會
Publication of HK1162522A1 publication Critical patent/HK1162522A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
HK12102352.4A 2007-10-23 2012-03-07 Oxidant resistant apolipoprotein a-1 and mimetic peptides a-1 HK1162522A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US98188707P 2007-10-23 2007-10-23
PCT/US2008/080898 WO2009055538A1 (en) 2007-10-23 2008-10-23 Oxidant resistant apolipoprotein a-1 and mimetic peptides

Publications (1)

Publication Number Publication Date
HK1162522A1 true HK1162522A1 (en) 2012-08-31

Family

ID=40336739

Family Applications (1)

Application Number Title Priority Date Filing Date
HK12102352.4A HK1162522A1 (en) 2007-10-23 2012-03-07 Oxidant resistant apolipoprotein a-1 and mimetic peptides a-1

Country Status (14)

Country Link
US (4) US8143224B2 (xx)
EP (3) EP2573113A3 (xx)
JP (1) JP5600065B2 (xx)
KR (1) KR20100100824A (xx)
CN (1) CN102177176B (xx)
AU (1) AU2008316811B2 (xx)
BR (1) BRPI0818881A2 (xx)
CA (1) CA2703962A1 (xx)
EA (1) EA201070517A1 (xx)
ES (1) ES2601830T3 (xx)
HK (1) HK1162522A1 (xx)
IL (1) IL205282A (xx)
MX (1) MX2010004514A (xx)
WO (1) WO2009055538A1 (xx)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20100100824A (ko) * 2007-10-23 2010-09-15 더 클리브랜드 클리닉 파운데이션 산화제 내성 아포지단백질 ａ-1 및 모방체 펩티드
US20130137628A1 (en) * 2010-05-11 2013-05-30 Esperion Therapeutics, Inc. Dimeric Oxidation-Resistant Apolipoprotein A1 Variants
AU2011268380A1 (en) 2010-06-15 2013-01-31 The Cleveland Clinic Foundation Compositions and methods for treating cancer
DK2767546T3 (en) * 2011-02-07 2019-02-04 Cerenis Therapeutics Holding Sa Lipoprotein complexes and their preparation and uses
US9610324B2 (en) 2012-07-11 2017-04-04 Esperion Therapeutics, Inc. Apolipoprotein mixtures
WO2015032841A2 (en) * 2013-09-05 2015-03-12 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for prevention or treatment of th17 mediated disease
SG11201609084QA (en) 2014-05-02 2016-11-29 Cerenis Therapeutics Holding Sa Hdl therapy markers
US10151764B2 (en) * 2014-05-15 2018-12-11 The Cleveland HeartLab Compositions and methods for purification and detection of HDL and ApoA1
JP2018528257A (ja) 2015-07-10 2018-09-27 ペプティノボ・バイオファーマ・リミテッド・ライアビリティ・カンパニーＰｅｐｔｉｎｏｖｏ Ｂｉｏｐｈａｒｍａ， ＬＬＣ 疎水性薬剤の効能を改善するための配合物
US10484742B2 (en) * 2016-07-26 2019-11-19 Umbo, Inc. Method and system for providing information to a user via a projection device
WO2019030575A1 (en) 2017-08-10 2019-02-14 Cerenis Therapeutics Holding APOMÈRES
ES2984285T3 (es) 2017-08-10 2024-10-29 Abionyx Pharma Sa Cargómeros
US10744087B2 (en) 2018-03-22 2020-08-18 Incarda Therapeutics, Inc. Method to slow ventricular rate
US20210231691A1 (en) * 2018-06-08 2021-07-29 The Cleveland Clinic Foundation Apoa1 exchange rate assays as a diagnostic for major adverse cardiovascular events
WO2021209823A1 (en) 2020-04-16 2021-10-21 Abionyx Pharma Sa Methods for treating acute conditions using lipid binding protein- based complexes
KR20230079132A (ko) 2020-10-01 2023-06-05 아비오닉스 파마 에스에이 안질환을 치료하는 데 사용하기 위한 지질 결합 단백질-기반 복합체를 포함하는 조성물
EP4322746A1 (en) 2021-04-15 2024-02-21 Abionyx Pharma SA Use of lipid binding protein-based complexes in organ preservation solutions
WO2023194798A1 (en) 2022-04-06 2023-10-12 Abionyx Pharma Sa Methods for treating leukocytosis, endothelial dysfunction and carditis using lipid binding protein-based complexes
WO2023194797A1 (en) 2022-04-06 2023-10-12 Abionyx Pharma Sa Methods for treating eye diseases using lipid binding protein-based complexes
WO2023237927A2 (en) 2022-06-10 2023-12-14 Abionyx Pharma Sa Methods for treating hyperinflammatory conditions using lipid binding protein -based complexes
WO2023237935A2 (en) 2022-06-10 2023-12-14 Abionyx Pharma Sa Methods for treating acute conditions using lipid binding protein-based complexes
WO2024150064A1 (en) 2023-01-13 2024-07-18 Abionyx Pharma Sa Lipid binding protein molecule therapy

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US6936694B1 (en) 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4904582A (en) 1987-06-11 1990-02-27 Synthetic Genetics Novel amphiphilic nucleic acid conjugates
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
SE9103701D0 (sv) 1991-12-13 1991-12-13 Kabi Pharmacia Ab Apolipoprotein
SE9203753D0 (sv) * 1992-12-11 1992-12-11 Kabi Pharmacia Ab Expression system for producing apolipoprotein ai-m
US20020064820A1 (en) * 2000-03-13 2002-05-30 Jean-Michel Dayer Apo-A-I regulation of T-cell signaling
US7144862B2 (en) 2000-08-24 2006-12-05 The Regents Of The University Of California Orally administered peptides to ameliorate atherosclerosis
WO2006012632A2 (en) 2004-07-23 2006-02-02 Xencor, Inc. Apolipoprotein a-1 derivatives with altered immunogenicity
AU2007229322B2 (en) * 2006-03-20 2012-04-05 Novartis Ag Method of treatment or prophylaxis inflammatory pain
KR20100100824A (ko) * 2007-10-23 2010-09-15 더 클리브랜드 클리닉 파운데이션 산화제 내성 아포지단백질 ａ-1 및 모방체 펩티드

Also Published As

Publication number Publication date
WO2009055538A1 (en) 2009-04-30
EP2212351B1 (en) 2017-09-13
EP2573113A3 (en) 2013-07-24
EP2520587B1 (en) 2016-08-10
BRPI0818881A2 (pt) 2015-05-05
MX2010004514A (es) 2010-07-28
JP5600065B2 (ja) 2014-10-01
US9051393B2 (en) 2015-06-09
EA201070517A1 (ru) 2010-12-30
EP2212351A1 (en) 2010-08-04
IL205282A0 (en) 2010-12-30
IL205282A (en) 2016-02-29
EP2573113A2 (en) 2013-03-27
US20120264677A1 (en) 2012-10-18
US9522950B2 (en) 2016-12-20
ES2601830T3 (es) 2017-02-16
US20140051624A1 (en) 2014-02-20
US20160024182A1 (en) 2016-01-28
EP2520587A2 (en) 2012-11-07
US20090149390A1 (en) 2009-06-11
CN102177176A (zh) 2011-09-07
EP2520587A3 (en) 2013-04-03
CN102177176B (zh) 2014-05-07
JP2011500832A (ja) 2011-01-06
KR20100100824A (ko) 2010-09-15
AU2008316811A1 (en) 2009-04-30
CA2703962A1 (en) 2009-04-30
US8143224B2 (en) 2012-03-27
US8536117B2 (en) 2013-09-17
AU2008316811B2 (en) 2015-01-22

Similar Documents

Publication Publication Date Title
HK1162522A1 (en) Oxidant resistant apolipoprotein a-1 and mimetic peptides a-1
IL225740A0 (en) Adapted factor vii polypeptides and uses thereof
HK1145506A1 (en) Peptides and their use
GB0712670D0 (en) Isolated peptides and uses thereof
IL218776A0 (en) Modified factor vii polypeptides and uses thereof
EP2318429A4 (en) PROMININ-1 PEPTIDE FRAGMENTS AND ITS USE
IL232394A0 (en) Peptides and epitopes against p2x7
HRP20150195T1 (xx) Antibakterijski peptidi
GB0702022D0 (en) Peptides and their use
EP2133416A4 (en) RECOMBINANT MICROORGANISM
IL195525A0 (en) Replikin peptides and uses thereof
GB0604187D0 (en) Peptide and uses thereof
EP2285827A4 (en) PEPTIDES AND ITS USE
SI2032708T1 (sl) Rekombinantni novirabdovirusi in njihove uporabe
EP2188305A4 (en) MODIFIED PEPTIDES HAVING TOXIN IMPROVING EFFECTS
EP2196477A4 (en) MODIFIED RECOMBINANT HUMAN ENDOSTATIN AND ITS APPLICATION
GB0617564D0 (en) Peptides and methods
IL192800A0 (en) Fgf2-binding peptides and uses thereof
GB0710813D0 (en) Peptides and uses thereof
GB0612873D0 (en) Isolated peptides and uses thereof
GB0816561D0 (en) Peptides and uses thereof
GB0800502D0 (en) Peptides and their uses
PL383574A1 (pl) Nowe białko i kodująca je sekwencja
GB0610452D0 (en) MHC binding peptides and their uses
GB0609896D0 (en) MHC binding peptides and their uses

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20181019